No Data
No Data
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics Receives Notice Of Allowance Covering Innovative Method Of Use For Lead Indication Ataxia-Telangiectasia; Allowance To Extend Into 2036 Patent Claims Related To Method Of Treating Patients With A-T Using The Company's Proprietary...
12 Health Care Stocks Moving In Monday's Pre-Market Session
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics Announces Publication Of 24-Month Safety Data For EryDex In Treating Ataxia-Telangiectasia, Highlighting Reduced Adverse Events Compared To Corticosteroids; Over 6K Monthly Doses Administered To Nearly 400 Patients In Ongoing Phase...
Express News | Quince Therapeutics Appoints Renowned Pediatric Neurologist DR. William Whitehouse to Scientific Advisory Board